Cleveland Precision Medicine Chronic Kidney Disease Cohort

目标。克利夫兰慢性肾脏疾病招募网站(CLE-CKD-RS)一直是KPMP的成员 自5年前成立以来，将继续招募一批患有糖尿病肾病的CKD患者 (DKD)和高血压可归因性CKD(H-CKD)，建立在我们已证明的成功的基础上。为了满足我们的 建议的招聘目标，我们将把患者筛查扩大到克利夫兰主校区普通诊所 医疗诊所和CKD诊所在区域设施中，重点放在为少数族裔社区服务的地点。CLE- CKD-RS将加强和扩大与不同社区的关系，以促进信任和确保 克利夫兰KPMP队列反映了肾脏疾病负担最重的人群。 背景资料。肾脏疾病很常见，成本很高，而且是致命的。肾脏精准医学项目(KPMP) 正在建立一个资源，其中将拥有患者级别的临床数据集和分子表型，以识别隐藏的、 肾脏疾病患者的临床可操作亚群，用于发现机制、生物标志物和 新的治疗方法。KPMP假设提出了多维患者数据的集成，在经济层面 分子数据和基因组序列的变异将产生必要的创新工具。 CLE-CKD-RS：与KPMP的协同作用和价值。在第一个资助周期中，CLE-CKD-RS研究团队 成功执行KPMP方案，以道德和安全的方式登记、活组织检查和保留不同的KPMP队列 参与者。此外，CLE-CKD-RS还设立了一个积极参与的社区咨询委员会，并使用 有机会向医学界和患者社区宣传KPMP，肾脏疾病的负担 以及促进肾脏健康的方法。尽管KPMP活动先是暂停，然后放慢了速度 针对COVID大流行的公共卫生反应，CLE-CKD-RS使用远程医疗工具跟踪我们的队列 并在允许的情况下迅速重新启动活动。这一经历为未来的黑天鹅赛事做好了准备。 CLE-CKD-RS小组的成员作为成员和领导人在KPMP工作组和委员会任职。 我们参与了机会池基金资助的两项CKD扩展临床表型研究和 通过赢得机会池资金，吸引其他当地调查小组加入KPMP。建立在 在这些成功的基础上，我们提出了以下里程碑： 1.每年从符合条件的H-CKD患者身上安全、合乎道德地收集30-40份研究用肾活检 或DKD，目标是在5年资助期内招收180名CKD参与者。 2.在整个供资周期内，保留90%的已登记参与者参加研究后续访问和活动。 3.在为黑人和西班牙裔社区服务的地区地点的CKD诊所启动KPMP招募活动 在第6年和第7年，将继续在这两个地点进行征聘，并在供资周期期间维持这些地点的征聘工作。 4.扩大教育和互惠方面的面对面、虚拟和现场社区参与活动 关于肾脏健康、KPMP参与和一般生物医学研究的互动。

Goals. The Cleveland Chronic Kidney Disease Recruiting Site (CLE-CKD-RS) has been a member of the KPMP since its inception 5 years ago and will continue to recruit a cohort of CKD patients with diabetic kidney disease (DKD) and hypertension-attributable CKD (H-CKD), building on our demonstrated successes. To meet our proposed recruiting targets, we will expand patient screening to the Cleveland Clinic main campus general medicine clinic and CKD clinics in regional facilities, focusing on sites that serve minority communities. The CLE- CKD-RS will strengthen and broaden its relationships with diverse communities to foster trust and ensure the Cleveland KPMP cohort reflects the people most burdened by kidney diseases. Background. Kidney diseases are common, costly and deadly. The Kidney Precision Medicine Project (KPMP) is building a resource, which will have patient-level clinical datasets and molecular phenotypes, to identify hidden, clinically actionable subgroups of people with kidney diseases for discovery of mechanisms, biomarkers and new treatments. The KPMP hypothesizes proposes integration of multidimensional patient data, omic level molecular data and variation in genome sequence will generate tools necessary for needed innovation. CLE-CKD-RS: synergy with and value to KPMP. In the first funding cycle the CLE-CKD-RS research team has successfully executed KPMP protocols to ethically and safely enroll, biopsy and retain a diverse cohort of KPMP participants. In addition, The CLE-CKD-RS has established an engaged Community Advisory Board and used opportunities to educate the medical and patient communities about the KPMP, the burden of kidney diseases and approaches to promote kidney health. Although KPMP activities were first suspended and then slowed by the public health response to the COVID pandemic, the CLE-CKD-RS used telehealth tools to follow our cohort and rapidly restarted activities when permitted. This experience has prepared for future black swan events. Members of the CLE-CKD-RS team serve on KPMP working groups and committees as members and leaders. We participate in two CKD extended clinical phenotyping studies funded by the Opportunity Pool funds and engaged other local investigative groups to join the KPMP by winning Opportunity Pool funding. Building upon these successes, we are proposing the following Milestones: 1. Safely and ethically collect 30-40 research kidney biopsies per year from eligible individuals with H-CKD or DKD with target aggregate enrollment of 180 CKD participants for the 5 year funding period. 2. Retain 90% of enrolled participants in research follow-up visits and activities throughout the funding cycle. 3. Initiate KPMP recruitment at CKD clinics in regional sites that serve the Black and Hispanic communities in years 6 and 7, respectively and maintain recruitment at those sites for the duration of the funding cycle. 4. Broaden in person, expand virtual and live community engagement activities for education and reciprocal interactions about kidney health, KPMP participation and biomedical research in general.